Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
Launched by MASSACHUSETTS GENERAL HOSPITAL · Jan 18, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help patients with advanced lung cancer who are experiencing breathlessness, a common and distressing symptom known as dyspnea. The study will test a program called BREEZE+, which includes three brief sessions with a nurse and access to a digital app. This app will teach patients skills to manage their breathing difficulties more effectively. The goal is to find out if this program can improve the quality of life for patients suffering from dyspnea.
To be eligible for the trial, participants must be at least 18 years old, have advanced lung cancer or mesothelioma, and report experiencing moderate to severe breathlessness. They should also be able to manage daily activities independently and read and respond to questions in either English or Spanish. Participants will receive support through the BREEZE+ program, and the findings from this trial may lead to better care options for patients in the future. Please note that the trial is not yet recruiting participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years
- • Diagnosis of advanced lung cancer (i.e., non-small cell lung cancer or small cell lung cancer) or mesothelioma, not being treated with curative intent
- • Self-report at least moderate dyspnea per a rating ≥4 on the validated 0-10 breathlessness item of the Edmonton Symptom Assessment Scale-Revised
- • Functioning independently per an Eastern Cooperative Oncology Group Performance Status ≤2
- • Ability to read and respond to questions in English or Spanish
- • Receiving primary cancer care at one of the participating institutions
- Exclusion Criteria:
- • Significant uncontrolled psychiatric disorder or other co-morbid disease (e.g., dementia, cognitive impairment), which the treating oncology clinician reports would prohibit the patient's ability to participate in study procedures.
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Coral Gables, Florida, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported